| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/FMC.13.140 |
| P698 | PubMed publication ID | 24144411 |
| P50 | author | Leonardo G Ferreira | Q83166751 |
| P2093 | author name string | Adriano D Andricopulo | |
| P2860 | cites work | Redox-active antiparasitic drugs | Q37961952 |
| Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis | Q37981773 | ||
| The trypanothione system and its implications in the therapy of trypanosomatid diseases | Q38034314 | ||
| Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity | Q41824183 | ||
| Pharmacophore-based 3D QSAR studies on a series of high affinity 5-HT1A receptor ligands | Q44107263 | ||
| An alternative form of melarsoprol in sleeping sickness | Q46219228 | ||
| Structure- and ligand-based structure-activity relationships for a series of inhibitors of aldolase. | Q51350782 | ||
| Synthesis and evaluation of substrate analogue inhibitors of trypanothione reductase. | Q54348844 | ||
| Principles of QSAR models validation: internal and external | Q56432346 | ||
| Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model | Q26778456 | ||
| Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography | Q27671819 | ||
| The bacterial redox signaller pyocyanin as an antiplasmodial agent: comparisons with its thioanalog methylene blue | Q27672885 | ||
| Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress | Q28144631 | ||
| The global burden of neglected tropical diseases | Q28259482 | ||
| Neglected tropical diseases | Q28267545 | ||
| Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism | Q28275518 | ||
| Dyes, trypanosomiasis and DNA: a historical and critical review | Q28298491 | ||
| Best Practices for QSAR Model Development, Validation, and Exploitation | Q28649930 | ||
| Investigation of trypanothione reductase as a drug target in Trypanosoma brucei | Q30897674 | ||
| Insights into the redox biology of Trypanosoma cruzi: Trypanothione metabolism and oxidant detoxification | Q37202974 | ||
| Chemotherapy against human African trypanosomiasis: is there a road to success? | Q37801690 | ||
| State of the art in African trypanosome drug discovery | Q37852737 | ||
| Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. | Q37891323 | ||
| Drug resistance in human African trypanosomiasis | Q37940573 | ||
| P433 | issue | 15 | |
| P921 | main subject | Trypanosoma brucei | Q33244 |
| P304 | page(s) | 1753-1762 | |
| P577 | publication date | 2013-10-01 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Inhibitors of Trypanosoma brucei trypanothione reductase: comparative molecular field analysis modeling and structural basis for selective inhibition | |
| P478 | volume | 5 |
| Q38668657 | Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors |
| Q45943914 | Development of Predictive QSAR Models of 4-Thiazolidinones Antitrypanosomal Activity using Modern Machine Learning Algorithms. |
| Q39329032 | Foreword. Trypanosomatid disease drug discovery and target identification |
Search more.